Sodium-ion batteries are promising candidates for next-generation large-scale energy storage owing to their abundance and low cost.Biphasic intercalation reactions,constrained by kinetic limitations and structural ins...Sodium-ion batteries are promising candidates for next-generation large-scale energy storage owing to their abundance and low cost.Biphasic intercalation reactions,constrained by kinetic limitations and structural instability,fundamentally restrict the rate capability and cycle life of sodium ion batteries.However,precise regulation of these reactions to enhance kinetics remains challenging.Here,we propose a strategy of atomic-scale phase engineering to activate the metastable state and achieve a three-phase reaction through precise Mg^(2+)doping at V sites in Na_(3)V_(2)(PO_(4))_(3).The Mg^(2+)occupancy promotes the exchange between Na1 and Na2 sites,thereby stabilizing a Na_(2)V_(2)(PO_(4))_(3) intermediate.First-principles calculations indicate that Mg^(2+)occupation facilitates charge redistribution by weakening Na-O electrostatic interaction,stabilizing the formation of Na_(2)V_(2)(PO_(4))_(3)phase.The optimized cathode exhibits ultrahigh capacity retention(84.5%after 5000 cycles at 3.51 A g^(-1)),supports ultrafast charging within 120 s,and exceptional rate capability(96.2 mAh g^(-1)at 4.68 A g^(-1)).This work establishes a universal route to unlock hidden reaction pathways by redefining the role of dopants in phase transition control.展开更多
Eradication of MRSA osteomyelitis requires elimination of distinct biofilms.To overcome this,we developed bisphosphonateconjugated sitafloxacin(BCS,BV600072)and hydroxybisphosphonate-conjugate sitafloxacin(HBCS,BV6307...Eradication of MRSA osteomyelitis requires elimination of distinct biofilms.To overcome this,we developed bisphosphonateconjugated sitafloxacin(BCS,BV600072)and hydroxybisphosphonate-conjugate sitafloxacin(HBCS,BV63072),which achieve“target-and-release”drug delivery proximal to the bone infection and have prophylactic efficacy against MRSA static biofilm in vitro and in vivo.Here we evaluated their therapeutic efficacy in a murine 1-stage exchange femoral plate model with bioluminescent MRSA(USA300LAC::lux).Osteomyelitis was confirmed by CFU on the explants and longitudinal bioluminescent imaging(BLI)after debridement and implant exchange surgery on day 7,and mice were randomized into seven groups:1)Baseline(harvested at day7,no treatment);2)HPBP(bisphosphonate control for BCS)+vancomycin;3)HPHBP(hydroxybisphosphonate control for HBCS)+vancomycin;4)vancomycin;5)sitafloxacin;6)BCS+vancomycin;and 7)HBCS+vancomycin.BLI confirmed infection persisted in all groups except for mice treated with BCS or HBCS+vancomycin.Radiology revealed catastrophic femur fractures in all groups except mice treated with BCS or HBCS+vancomycin,which also displayed decreases in peri-implant bone loss,osteoclast numbers,and biofilm.To confirm this,we assessed the efficacy of vancomycin,sitafloxacin,and HBCS monotherapy in a transtibial implant model.The results showed complete lack of vancomycin efficacy while all mice treated with HBCS had evidence of infection control,and some had evidence of osseous integrated septic implants,suggestive of biofilm eradication.Taken together these studies demonstrate that HBCS adjuvant with standard of care debridement and vancomycin therapy has the potential to eradicate MRSA osteomyelitis.展开更多
基金finally supported by the National Natural Science Foundation of China(NSFC Grants 52074098)the Major Science and Technology R&D Special Project in Jiangxi Province(104 Ah high specific energy and fast charging function lithium-ion battery system development and application project 20233AAE02009)the Cospowers Technology Co.,Ltd.,Technology Project Funding(research on key materials and battery technologies for sodium ion batteries,KYDY2022003)。
文摘Sodium-ion batteries are promising candidates for next-generation large-scale energy storage owing to their abundance and low cost.Biphasic intercalation reactions,constrained by kinetic limitations and structural instability,fundamentally restrict the rate capability and cycle life of sodium ion batteries.However,precise regulation of these reactions to enhance kinetics remains challenging.Here,we propose a strategy of atomic-scale phase engineering to activate the metastable state and achieve a three-phase reaction through precise Mg^(2+)doping at V sites in Na_(3)V_(2)(PO_(4))_(3).The Mg^(2+)occupancy promotes the exchange between Na1 and Na2 sites,thereby stabilizing a Na_(2)V_(2)(PO_(4))_(3) intermediate.First-principles calculations indicate that Mg^(2+)occupation facilitates charge redistribution by weakening Na-O electrostatic interaction,stabilizing the formation of Na_(2)V_(2)(PO_(4))_(3)phase.The optimized cathode exhibits ultrahigh capacity retention(84.5%after 5000 cycles at 3.51 A g^(-1)),supports ultrafast charging within 120 s,and exceptional rate capability(96.2 mAh g^(-1)at 4.68 A g^(-1)).This work establishes a universal route to unlock hidden reaction pathways by redefining the role of dopants in phase transition control.
基金supported by grants from the National Institutes of Health(SBIR R44 AI125060,NIAMS P50 AR072000,and NIAMS P30 AR069655)。
文摘Eradication of MRSA osteomyelitis requires elimination of distinct biofilms.To overcome this,we developed bisphosphonateconjugated sitafloxacin(BCS,BV600072)and hydroxybisphosphonate-conjugate sitafloxacin(HBCS,BV63072),which achieve“target-and-release”drug delivery proximal to the bone infection and have prophylactic efficacy against MRSA static biofilm in vitro and in vivo.Here we evaluated their therapeutic efficacy in a murine 1-stage exchange femoral plate model with bioluminescent MRSA(USA300LAC::lux).Osteomyelitis was confirmed by CFU on the explants and longitudinal bioluminescent imaging(BLI)after debridement and implant exchange surgery on day 7,and mice were randomized into seven groups:1)Baseline(harvested at day7,no treatment);2)HPBP(bisphosphonate control for BCS)+vancomycin;3)HPHBP(hydroxybisphosphonate control for HBCS)+vancomycin;4)vancomycin;5)sitafloxacin;6)BCS+vancomycin;and 7)HBCS+vancomycin.BLI confirmed infection persisted in all groups except for mice treated with BCS or HBCS+vancomycin.Radiology revealed catastrophic femur fractures in all groups except mice treated with BCS or HBCS+vancomycin,which also displayed decreases in peri-implant bone loss,osteoclast numbers,and biofilm.To confirm this,we assessed the efficacy of vancomycin,sitafloxacin,and HBCS monotherapy in a transtibial implant model.The results showed complete lack of vancomycin efficacy while all mice treated with HBCS had evidence of infection control,and some had evidence of osseous integrated septic implants,suggestive of biofilm eradication.Taken together these studies demonstrate that HBCS adjuvant with standard of care debridement and vancomycin therapy has the potential to eradicate MRSA osteomyelitis.
